These observations were followed by a logical translation of the laboratory findings into a phase I/II clinical study that has now demonstrated significant clinical activity in patients with advanced estrogen receptor-positive (ER+) breast cancer [9]. This evidence concerns the gene ESR1 and breast carcinoma.